3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
88
Gastrointestinal
10
Head & Neck
7
Breast
7
Thoracic
5
Sarcoma
4
Lymphoid
4
Dermatologic
4
Gynecologic
3
Other solid neoplasm
1
Other hematologic neoplasm
1
Other
1
NET
1
Myeloid
1
Endocrine
1
Classical hematology
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
191
Anemia, Refractory, with Excess of Blasts
179
Myelodysplastic Syndromes
175
Leukemia
168
Precursor Cell Lymphoblastic Leukemia-Lymphoma
132
Neoplasms
121
Multiple Myeloma
116
Venous Thromboembolism
111
Anemia
108
Leukemia, Myelomonocytic, Chronic
103
Leukemia, Lymphocytic, Chronic, B-Cell
100
Myeloproliferative Disorders
99
Lymphoma, Non-Hodgkin
97
Lymphoma
96
Hodgkin Disease
85
Thrombocytopenia
84
Anemia, Aplastic
79
Primary Myelofibrosis
67
Lymphoma, Follicular
67
Hematologic Neoplasms
63
Leukemia, Myeloid, Chronic-Phase
61
Lymphoma, Mantle-Cell
59
Febrile Neutropenia
59
Congenital Abnormalities
59
Neoplasms, Plasma Cell
57
Leukemia, Myeloid, Accelerated Phase
57
Anemia, Refractory
57
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
56
Blast Crisis
56
Burkitt Lymphoma
53
Interventions
Rivaroxaban
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urologic Neoplasms
×
Classical hematology
×
Clear all
NCT05920343
2025-07-10
PREVENT-GU
Ottawa Hospital Research Institute
Phase 2/3
Recruiting
120 enrolled